What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short answer

• The FDA cracked down on compounding of GLP‑1 drugs (semaglutide, tirzepatide and similar) because many compounded products were unapproved copies of biologic drugs, raised sterility and dosing-safety concerns, and appeared to fall outside the limited circumstances where compounding is lawful. The agency issued warning letters and public advisories and has been asking pharmacies/outsourcing facilities to stop making or distributing those products.
• Who’s still operating legally? FDA‑approved manufacturers and pharmacies dispensing FDA‑approved GLP‑1 drugs are legal (e.g., Novo Nordisk’s Wegovy/Ozempic/Rybelsus, Eli Lilly’s Mounjaro/Zepbound). Some compounding operations may still legally compound GLP‑1s only in very narrow, patient‑specific situations consistent with federal and state law (and only if they meet applicable 503A or 503B requirements and aren’t making unapproved “copies” of licensed biologics). The specifics depend on whether the pharmacy is a state‑licensed 503A compounding pharmacy (patient‑specific) or an FDA‑registered 503B outsourcing facility (cGMP, non‑patient specific) and on recent FDA enforcement about biologics.

What led to the crackdown (brief)

• Huge demand for GLP‑1s led to pharmacies and clinics compounding semaglutide/tirzepatide formulations for weight loss or diabetes.
• FDA concerns:
  • Many compounded products were effectively copies of FDA‑approved biologics (not permitted).
  • Sterility, dose accuracy, labeling and quality/testing issues with compounded injectable biologics.
  • Public reports of adverse events and variable potency.
• FDA response: public safety alerts, warning letters to specific pharmacies/outsourcing facilities, and enforcement actions where warranted. The agency has emphasized that compounding copies of approved biologics is generally inconsistent with the law.

Who is clearly legal to use instead (recommended, by name)

• Use FDA‑approved GLP‑1 drugs dispensed through licensed pharmacies or manufacturer specialty hubs:
  • Novo Nordisk: Wegovy (semaglutide for weight loss), Ozempic (semaglutide for diabetes), Rybelsus (oral semaglutide).
  • Eli Lilly: Mounjaro (tirzepatide for diabetes), Zepbound (tirzepatide for weight management, if/where marketed).
• These products have gone through FDA review for safety/quality and are the safest legal route.

When compounding might still be legal (and what to check)

• Compounding is limited to specific circumstances (generally patient‑specific prescriptions under 503A or tightly regulated 503B outsourcing facilities). FDA’s position has been that routinely compounding versions of an approved biologic is not appropriate.
• If a clinician or pharmacy proposes a compounded GLP‑1, you should verify:
  • Is there a patient‑specific prescription?
  • Is the pharmacy a registered 503B outsourcing facility (check FDA’s 503B registry) or a licensed 503A with state board oversight?
  • Can the pharmacy provide sterility test results, COA (certificate of analysis) and proof of appropriate handling and storage?
  • Is the product being represented as an FDA‑approved drug (it should not be if it’s compounded)?

How to verify current legal status for a specific provider/product

• Search the FDA Warning Letters and Enforcement Reports pages for that pharmacy or product.
• Check the FDA 503B Outsourcing Facility Registry (for outsourcing facilities).
• Check your state board of pharmacy license status and any state enforcement notices.
• Ask the pharmacy/clinic for their FDA/board registrations and batch testing documents; consult your prescribing clinician.

If you want, I can:

• Look up whether a particular compounding pharmacy or clinic has an FDA warning letter or is on the 503B registry (give me the exact name and location).
• Help you find legitimate dispensing options and manufacturer specialty pharmacies for the FDA‑approved GLP‑1 you or your prescriber wants.

Note: my information is current through June 2024. If you need the very latest enforcement actions after that date I can search the FDA site or public records now if you give me a name to check.